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ABSTRACT 
Pneumococcal disease is a healthcare concern with increasing financial and 
societal burden for adults over the age of 65 years and their caretakers.  The Center for Disease 
Control and Prevention (CDC) recommends the use of pneumococcal vaccines in this population 
as a preventive measure helping minimize the mortality and morbidity.  This project aimed at 
increasing the rate of pneumococcal vaccines in a Federally Qualified Health Center 
(FQHC).  The interventions implemented included the use of audit, feedback and provider 
educational intervention aimed at increasing the knowledge and the intent to change and improve 
their practice.  The key results indicated an increase in aggregate pneumococcal vaccines in the 
organization as well as an increase in individual and historical vaccination rates for the 
organization and individual providers.  The implications for practice include the improvement in 
vaccination rates significantly impacting the health of the community, as well as an increase in 
education provided regarding vaccination.  The questionnaire provided positive feedback on the 
intervention.  Further research to determine vaccination availability and re-vaccination should be 
considered. 
Keywords: pneumococcal vaccine, older adults, chart audit, and provider feedback. 
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SECTION ONE: INTRODUCTION 
 Pneumococcal disease is a healthcare concern that could be detrimental to the health of 
the population, exposing an increasing financial and societal burden for adults over the age of 65 
years and their caretakers.  The use of pneumococcal vaccines is a preventive measure helping 
minimize the mortality and morbidity in this population, as well as improving the quality of life 
of individuals (Mangen, Huijts, Bonten & de Wit, 2017).  The Center for Disease Control and 
Prevention (CDC) recommends individuals over the age of 65 to receive the pneumococcal 
vaccine to prevent the severe consequences of this disease process.  The selected Federally 
Qualified Health Center (FQHC) for the project has a low rate of pneumococcal vaccination in 
the selected population, evidencing the risks of the community.  In 2016, there were 98 
pneumonia (PNA) and influenza deaths in the city of Richmond, VA (CDC, n.d.).  The use of 
audit and feedback as a tool to improve professional practice is established as an effective way to 
influence health professional behaviors (Ivers et al., 2012).  The purpose of this project was to 
implement a chart audit and provider educational intervention aimed at increasing the 
pneumococcal vaccination rates in adults older than 65 years of age in the FQHC.  The project 
also evaluated the providers’ intent to improve their practice based on the information provided. 
Background  
 PNA is an infection of the lungs and can lead to mild and severe illness in people all 
ages, with higher risk in individuals 65 years of age and older (CDC, 2017a).  Community-
acquired pneumonia (CAP) is a common cause of hospitalization in the elderly, while invasive 
pneumococcal disease (IPD) is the most severe form of pneumococcal disease (Falkenhorst, 
Remschmidt, Harder, Hummers-Pradier, Wichmann & Bogdan, 2017). 
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 The role of infections continues to play a crucial part in mortality of older adults, with 
PNA being one of the most severe infections, especially among men and women over 85 years of 
age (CDC, 2005).  The CDC (2005) estimates the 30-day death rate of PNA is 11% to 70%, 
depending on the type of PNA and comorbidities of the individual.  In adults over the age of 65, 
PNA can be deadly.  Pneumococcal pneumonia kills about one out of 20 individuals who 
contract it while Pneumococcal bacteremia kills about one out of five individuals infected (CDC, 
2017b).  Pneumococcal meningitis causes death in about one in five individuals with the disease 
(CDC, 2017b). 
An estimated 1.3 million annual cases of CAP affect adults over the age of 65 years, 
nearly 40% of these episodes will result in a hospitalization averaging 5.6 days of inpatient 
services (Brown, Harnett, Chambers & Sato, 2018).  The financial burden for each episode can 
reach an excess of $18,000, causing Medicare an estimated $13 billion annually (Brown et al., 
2018).  This number is expected to grow with the increasing older population in the United 
States since elderly residents are increasing at twice the rate of the general population (CDC, 
2005).  The future economic cost of PNA hospitalization could increase annually by $2.5 billion 
(Drijkoningen & Rohde, 2014).  CAP risk increases with age, from 18.2 cases per 1,000 
person/years in the 65 to 69 year-old population, to 52.3 cases per 1,000 person/years in 
individuals older than 85 years of age (Brown et al., 2018). 
The Food and Drug Administration (FDA) approved two vaccines to prevent 
pneumococcal disease.  The Pneumococcal conjugate vaccine (PCV13 or Prevnar 13) includes 
purified capsular polysaccharide of 13 serotypes of Streptococcus pneumoniae (CDC, 2017a).  
The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), a randomized, 
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double-blind placebo-controlled trial of 84,496 community-dwelling immunocompetent adults 
over 65 years of age demonstrated: 
 45.6% efficacy of PCV13 against vaccine-type pneumococcal pneumonia 
 45.0% efficacy against vaccine-type non-bacteremic pneumococcal pneumonia 
 75.0% efficacy of PCV13 against vaccine-type IPD (CDC, 2017a). 
The pneumococcal polysaccharide vaccine (PPSV23 or Pneumovax 23) contains antigens 
from 23 types of pneumococcal bacteria (CDC, 2017a).  This vaccine is 60% to 70% effective in 
preventing invasive disease (CDC, 2017a).  The CDC (2017a) recommends the following 
guidelines in the use of pneumococcal vaccines:  
 Give a dose of PCV13 to adults 65 years or older who have not previously received a 
dose. Then administer a dose of PPSV23 at least one year later. 
 If the patient already received one or more doses of PPSV23, give the dose of PCV13 at 
least one year after they received the most recent dose of PPSV23. 
To further support the use of the vaccines, studies show that at least one dose of 
pneumococcal vaccine protects 75 in 100 older adults against invasive pneumococcal disease and 
45 in 100 older adults against pneumococcal PNA (CDC, 2017a).  Despite the efficacy of these 
vaccines, the current rate of vaccination in the older adult population ranges from 59.7% to 
66.9% (CDC, 2017a), leaving a significant percentage of the community at increased risk and 
vulnerable to this disease. 
Also, relevant to the project are health disparities and the incidence of chronic disease in 
the elderly.  In 2006, African American men older than 65 years of age were nearly 7% more 
likely to die from influenza and PNA than their counterpart in the Caucasian population 
(American Lung Association [ALA], 2010).  These numbers exposed that African Americans are 
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37% less likely than Caucasians to be vaccinated against PNA, while Hispanics are 46% less 
likely to be vaccinated against PNA than Caucasians (ALA, 2010). 
The project took place in a FQHC with a low rate of pneumococcal vaccination 
documented in the patient’s charts.  Preliminary data shows that 3% of adults over the age of 65 
who were seen by providers between January 1, 2018, and June 30, 2018, have a documented 
pneumococcal immunization.  Documentation indicates that the vaccine was received in the 
clinic.  Providers can also document if the patient refused to receive the vaccine in the preventive 
medicine section of the medical record; this can be determined by chart review only.  
Immunizations received at another facility are documented historically in the immunization 
section. 
Problem Statement  
 Pneumococcal disease is a serious condition increasing the risks of complications and 
decreasing quality of life for adults older than 65 years of age (CDC, 2017a).  The CDC 
recommends scheduled vaccinations in this population to prevent this complicated and possibly 
fatal illness (2017a).  The patients at the FQHC are at higher risk of contracting this preventable 
disease due to the low rate of pneumococcal vaccines documented, but also due to the population 
characteristics.  Preliminary data shows only 3% of the selected population had received the 
immunization this year.  This fact exposes the gap in quality of care related to pneumonia 
prevention in the community of individuals over 65 years of age and older. 
Purpose of the Project 
 The purpose of this project was to implement a chart audit and provider educational 
intervention aimed at increasing the Pneumococcal vaccination rates in adults older than 65 years 
of age in the FQHC.  The project also aimed to improve the provider’s intent to improve their 
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practice related to Pneumococcal immunizations.  The chart audit was used to determine 
Pneumococcal vaccination practices and documentation.  The educational intervention 
incorporated current recommendations by the CDC, as well as resources describing efficacy, 
benefits, and vaccination schedules. 
Clinical Question 
In providers working at a FQHC (P), does a chart audit and educational feedback 
intervention (I) increase pneumococcal vaccination rate in older adults (O)? 
SECTION TWO: LITERATURE REVIEW 
A literature review was conducted to evaluate current guidelines for pneumococcal 
vaccination, as well as effectiveness and safety.  The information researched also focused on the 
impact of vaccination, financial and health-related, and resources for educational interventions.  
These topics were selected as all-inclusive areas of interest when analyzing PNA immunization, 
overarching to provide an understanding of the possible challenges preventing vaccination in 
older adults, as well as strategies to address the problem in similar settings. 
Search Strategy 
Pneumonia vaccine.  A literature search was completed using PubMed, CINAHL, and 
MEDLINE.  The search strategy includes keywords: Pneumococcal vaccine, older adults, 
elderly, seniors, geriatrics.  The parameters of the search contained articles published in the 
English language within the last five years.  Peer-reviewed articles and full-text articles were 
considered for review.  A total of 266 articles were found.  After reviewing abstracts and 
synopsis, 15 articles were selected. Articles with lower Melnyk level of evidence or opinions 
were excluded, from the remaining collection, the project leader chose articles in different 
categories with higher Melnyk level of evidence.  The first 15 articles with these characteristics 
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were selected.   These articles encompass the broad spectrum of the project and help understand 
the need for a project to increase pneumococcal vaccination rate in primary care and its impact 
on the older population.   
Audit and feedback.  A literature search was also completed using the same databases 
utilizing the keywords audit and feedback.  The parameters of the search contained articles 
published in the English language within the last ten years.  Peer-reviewed articles and full-text 
articles were considered for review.  A total of 3043 articles were found, further evaluation of 
articles for systematic reviews and meta-analysis yielded 161 articles.  After reviewing abstracts 
and synopsis, four articles were selected based on the level of evidence and the use of both, audit 
and feedback in clinical practice.   
Critical Appraisal 
Pneumonia vaccine.  The articles selected were analyzed individually, and as a whole; 
the appraisal was completed using the Melnyk Levels of Evidence.  From the 15 articles 
selected, five articles were level one, indicating systematic review, meta-analysis, and guidelines.  
One article was level two, a random controlled trial (RTC).  The next six articles belong to level 
four, describing cohort studies or pilot tests.  From the last three articles, one is level five and 
two are level seven.  These articles are used to provide background information to evaluate 
possible educational content.  A table of evidence for each article is located in Appendix A.  
Some of the research analyzed was developed in foreign countries, which could pose some 
limitations.  Data analysis is also performed utilizing current CDC guidelines, which help ground 
clinical practice in the United States.  
The FDA licensed PCV13 in 2010 based on studies comparing serological response in 
children who received PCV13 to PCV7 (CDC, 2017a).  Immunogenicity and vaccine efficacy in 
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older adults was conducted in the CAPiTA trial from 2008 to 2013 (CDC, 2017a).  Evidence 
from this trial provided signs suggesting benefits of PCV13 vaccination in older adults, resulting 
in lower IPD incidence among unvaccinated persons of all ages (CDC, 2017a).  Vaccination with 
PPSV23 shows that more than 80% of healthy adults vaccinated develop antibodies against the 
serotypes contained in the vaccine, with an immune response within two to three weeks (CDC, 
2017a).  The CDC (2017a) indicates that older adults, as well as people with some chronic 
conditions or immunodeficiency, may not respond as well with antibodies declining quicker than 
in healthy adults.  Overall, PPSV23 is 60% to 70% effective in preventing invasive disease 
(CDC, 2017a).  The PNA vaccination rate in older adults was 63.6%, indicating that more than 
six out of 10 individuals were vaccinated.  This group was characterized by individuals older 
than 75 years of age, non-Hispanic white, and not poor (CDC, 2017a), pointing to health 
discrepancies in the health system.  Based on this evidence, the literature review will focus on 
vaccine immunogenicity and effectiveness, the financial and societal burden of PNA, and 
strategies to increase the vaccination rate in specific settings.  
The systematic review by Remschmidt, Harder, Wichmann, Bogdan & Falkenhorst 
(2016) did not include any reports on the effectiveness of pneumococcal vaccination, the sections 
on immunogenicity and re-vaccination are still considered in this review.  Huss et al.’s (2009) 
results on all-cause mortality in double-blind trials and the little evidence of vaccine protection 
among the elderly contradict other research.  This article was analyzed, and although a level one 
on the Melkyn evidence grading, the results will not be included at this time.  Several articles 
were included to take notice of the financial burden of pneumococcal disease and explore, not 
only the health risks of the disease but also the economic consequences, personal and societal.  
The article by Drijkoningen & Rohde (2014) was included to provide clinical information in the 
PNEUMOCOCCAL IMMUNIZATION IN OLDER ADULTS  17 
 
disease process.  This resource, along with the CDC and guidelines by the Infectious Diseases 
Society of America (IDSA) and the American Thoracic Society (ATS) (Mandell et al., 2007), 
provided grounded knowledge to incorporate in the educational intervention. 
Audit and feedback.  The articles selected were analyzed individually, and an appraisal 
was completed using the Melnyk Levels of Evidence.  The four articles selected are level one, 
indicating systematic review and meta-analysis.  These articles provide evidence of the 
effectiveness of a chart audit and feedback on the improvement of professional practice (Ivers et 
al., 2012) 
Synthesis 
 Pneumonia vaccine.  There were consistent reports across the articles indicating the 
benefits of the pneumococcal vaccine and the risks of remaining unvaccinated.  Baldo et al. 
(2016) concluded that there is a high mortality rate among older patients admitted to the hospital 
for pneumonia and indicated that the PCV13 vaccine has a protective role against the disease.  
The study by Mangen et al. (2017) reported lower quality of life in the cohort of patients 
surviving hospitalization for CAP and a six fold-increase of mortality in individuals diagnosed 
with CAP.  Literature also shows several categories, pointing at the full benefits of 
pneumococcal immunization.  These categories include (a) healthcare cost savings, (b) health 
gains, (c) prevention of comorbidities, (d) risk reductions, and (d) decrease in nosocomial 
infections (Cafiero-Fonseca et al., 2017). 
 The financial burden of contracting PNA is rising.  The hospitalization rate for older 
adults diagnosed with PNA in increasing, showing a 20% surge in the period between 1988-1990 
and 2000-2002 (Vila-Corcoles & Ochoa-Gondar, 2015).  Calculations of hospitalization costs 
due to CAP are expected to be between $7000 and $8000 per episode (Vila-Corcoles & Ochoa-
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Gondar, 2015).  Given these numbers and the increased elderly population, prevention is crucial.  
The vaccination cost for CAP is approximately $40.2 million; this amount includes 
pneumococcal and influenza vaccines (Brown et al., 2018). 
 Two articles were evaluated for innovating strategies that could be used in a primary care 
setting to increase the rate of pneumococcal vaccination.  One study evaluated the 
implementation of a standing order program (SOP) for staff to assess the individuals’ 
immunization states, ascertain if a pneumococcal vaccine is appropriate, and administer the 
vaccine (Nowalk et al., 2014).  This approach is underutilized in primary care offices, but the 
proper utilization and evaluation of this tools can potentially increase the vaccination rate.  Park 
et al. (2016) proposed the implementation of a program that would increase vaccination rates by 
(a) implementing a protocol, (b) staff education, (c) identification of eligible patients, and (d) 
automated outreach and immunization scheduling.  Although the project was not implemented, it 
offers a protocol that could be adapted to a FQHC.   One major challenge would be the financial 
resources to implement and sustain the plan. 
 Finally, and most relevant, is the data pertaining to vaccine efficacy and effectiveness.  
Studies by Falkenhorst et al. (2017) and Mandell et al. (2007) support the overall effectiveness of 
PCV23 against invasive pneumococcal disease on people over the age of 65 years.  The article 
describing the guidelines by the DSA and ATS  by Mandell et al. (2007) indicated that efficacy 
may decrease with age, supporting Remschmidt et al. (2016) concepts of re-vaccination.  The use 
of PCV13 is also reinforced as safe and effective by Deursen et al. (2018), reducing the first 
episode of CAP and IPD. 
 Audit and feedback.  The Cochrane review of audit and feedback (Ivers et al., 2012) 
concluded that this process could lead to small but potentially important improvement in 
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professional practice.  This analysis was supported by the subsequent secondary analysis by Ivers 
et. al (2014), also indicating that audit and feedback is most effective in specific circumstances 
such as (a) delivered by a supervisor or respected colleague, (b) presented frequently, (c) 
featuring both specific goals and action-plans, (d) aiming to decrease the targeted behavior, (e) 
baseline performance is lower, and (f) recipients are non-physicians.  Colquhoun et al. (2013) 
also utilized the Cochrane review to evaluate the use of theories in the development and 
implementation of audits and feedback.  The results from the analysis indicated that the explicit 
use of theories was rare (Colquhoun et al., 2013).  Tuti et al. (2017) aimed at determining the 
effectiveness of electronic audit and feedback and encountered that given the heterogeneity of 
the studies, the effects of using an electronic approach was highly variable. 
Conceptual Framework/Model 
 The Iowa Model was used as a conceptual framework for this project.  This model 
provides a guideline for the implementation of evidence-based practice (EBP) in a variety of 
settings, focusing on organization and collaboration (Iowa Model Collaborative, 2017).  
Permission to use the framework and its tools has been obtained (Appendix E).  The Iowa Model 
has several steps: (a) identify a problem, (b) form a team, (c) gather evidence, (d) critique and 
synthesize the evidence, (e) determine the validity and appropriateness of the evidence, (f) pilot 
change, (g) determine if the change is appropriate for practice, (h) implement, and (i) 
disseminate results (Iowa Model Collaborative, 2017).  This model has several key features: 
 Use of flowchart to guide decision-making 
 Use of problem-solving steps 
 Use of feedback loops to guide changes in processes 
 Interdisciplinary approach (Schaffer, Sandau & Diedrick, 2013). 
PNEUMOCOCCAL IMMUNIZATION IN OLDER ADULTS  20 
 
 The first step in the Iowa Model is to identify a problem for the organization, either a 
problem-focused or knowledge-focus trigger (Brown, 2014).  Problem-focused triggers arise 
from risk management and financial data, or a clinical problem; knowledge-focused triggers 
derive from new research findings, or new practice guidelines are identified (Brown, 2014).  
Once the problem is identified, the project leader needs to determine if it is a priority for the 
organization, issued with higher volume or higher cost will have priority and will assist in the 
organizational buy-in process (Brown, 2014).  Then, the team is selected, with an 
interdisciplinary approach, to develop, evaluate and implement the EBP change (Brown, 2014).  
The next step is to gather and critique pertinent research and develop a problem question 
(Brown, 2014).  At that point, the team needs to determine if sufficient research exists to 
implement a practice change (Brown, 2014).  If there is no sufficient evidence, then further 
research needs to be conducted.  If the data is sufficient, a pilot test can be implemented.  If the 
intervention is successful, the change can be adapted to an organizational change (Brown, 2014) 
and results disseminated. 
 The project investigated a problem-focused issue for the organization, the low rate of 
pneumococcal immunization in older adults.  The next step was to form a team to address this 
problem.  The stakeholders were selected based on the topic, and were responsible for the 
development, implementation, and evaluation of the plan.  The team leader was the DNP student.  
The project leader was also responsible for literature review and identifying appropriate 
resources.  The project leader then critiqued, synthesized and evaluated the validity of data; the 
information used in the project was based on EBP and current clinical guidelines.  The team used 
the CDC’s recommendation and scheduled immunization guidelines as a reference for all 
educational interventions and resources.  Once the evidence was sufficient, the project leader 
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designed and implemented the intervention selected.  For this project, several factors needed to 
be taken into account (a) willingness of providers to participate in the project, (b) organizational 
resources, (c) time constraints, and (d) consistency between different offices.  The chart audit 
provided aggregate and individual data to be included in the educational intervention.  The 
aggregate data was disseminated to all providers, and each provider received individual feedback 
based on their audits.  The interventions selected included providing evidence-based information 
to providers in a teaching format completed in the different locations as well as resource 
materials such as immunization schedules and information sheets.  After the educational 
intervention was finalized, the providers completed a questionnaire indicating their intent to 
change their practice based on the information provided.  The project leader then encouraged the 
providers to implement the knowledge provided and apply guidelines into practice.  The next 
step in the Iowa Model was to collect and report post-intervention data.  This data assisted in 
determining the outcomes of the project and if the implementation was appropriate for the 
practice.  At this point, the project leader met with providers and the Chief Medical Officer 
(CMO) to disseminate findings and obtain input.  A sustainable practice change was set to 
continue the analysis of performance data on a quarterly basis and report the findings during the 
providers’ meetings.   
Summary  
  The literature review yielded important information regarding pneumococcal 
immunization.  The benefits of the vaccine and risk of PNA were established, but still, a large 
number of patients at the FQHC remain unvaccinated.  The financial burden of hospitalization 
and the quality of life of individuals who contracted the disease increased the risks of 
comorbidities and mortality in the elderly population.  The current guidelines of the CDC, and 
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recommendations by DSA and ATS encouraged the implementation of strategies to ensure 
pneumonia vaccination in older adults. Preventive measures are critical to ensuring that 
individuals over the age of 65 years are vaccinated.  The literature addressed the effectiveness 
and efficacy of the pneumococcal immunization, but more research is needed regarding 
interventions to increase the vaccination rate. The purpose of this project is to increase the rate of 
pneumococcal immunizations in older adults in primary care.  The project focused on chart 
audits and feedback, as well as educational interventions for providers in the FQHC to impact the 
number of individuals over 65 years of age vaccinated against PNA.  The providers also 
completed a questionnaire indicating their intent to change their practice based on the 
information received. 
SECTION THREE: METHODOLGY 
Design  
 The EBP project followed a quasi-experimental design evaluating the rate of 
pneumococcal vaccination before and after the educational intervention.  This EBP project also 
followed the Iowa Model to guide the process and decision-making.  The selection of this project 
design is congruent when randomization is not logistically feasible in the chosen setting (Harris 
et al., 2006).  The intervention phase was implemented in a 30-day time frame, allowing for 
educational interventions and the understanding and allocation of written materials provided.  
The project leader performed chart audits and feedback focusing on documentation related to 
PNA vaccination for each provider in the clinics.  An intervention implementing audits and 
feedback is based on the assumption that healthcare professionals will modify their practice 
when provided with performance feedback indicating that their clinical practice is inconsistent 
with a specific target (Ivers et al., 2012).  The intent to change practice survey was used to 
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determine the impact of this intervention on clinical practice.  This method is more effective 
when the audit and feedback are provided more than once, is given verbally and in writing, and 
include specific targets and an action plan (Ivers et al., 2012).  The educational intervention was 
implemented once IRB approval was completed.  This educational intervention was focused on 
providers’ practices and consisted on an instructional meeting, with information provided 
verbally and in written form.  The rate of pneumococcal immunization in the selected population 
was collected pre-and post-intervention.  This information was obtained utilizing Electronic 
Medical Records (EMR) reporting and audits. 
Measurable Outcomes  
 Outcome 1: Increase the aggregate pneumococcal vaccination rate in patients over the 
age of 65 years.   
 Outcome 2: Increase in individual providers’ pneumococcal vaccination rate in patients 
over the age of 65 years.   
 Outcome 3: Provider intent to change and improve their practice based on the 
interventions.   
Setting 
 The project took place at the Capital Area Health Network (CAHN), a FQHC in the 
Richmond area.  This FQHC offers several services: primary care, mental health, wellness, 
dental and diabetes education.  CAHN has six locations in the Richmond Area, each site 
provides primary care services, two locations offer dental services, and one site has mental health 
services.  Most insurances are accepted, but a large number of patients are uninsured and 
underinsured.  For patients who are uninsured, payment for services is based on income and 
determined by a sliding scale fee, ranging from $35 to $150 per appointment.  A flat laboratory 
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fee of $15 will include all tests ordered during the appointment.  The organization also accepts 
Virginia Coordinate Care, a program offered by the Virginia Commonwealth University Medical 
Center, for uninsured individuals who meet the financial qualifications.  This program offers 
access to affordable care in the Greater Richmond Area (VCU Health, n.d.).  CAHN is a 
community partner providing primary care services for individuals with VCC.  Given the 
characteristics of the population, health disparities are evident, making a gap in care and lack of 
preventive services a crucial step for the health of the community.   
CAHN is committed to improving the health of the community with preventive medicine 
and to eliminating health disparities (CAHN, 2018).  The organization’s vision is to promote 
social responsibility, improve health equity, and optimize the quality of life of the community 
(CAHN, 2018).  These values support the project by utilizing preventive services to ensure older 
adults decrease their risk of contracting PNA and reducing the associated risks.  The CMO was 
informed of the project in several conversations; he had verbally agreed to support the project at 
the last meeting on June 2018.  A copy of the project site support letter is included in Appendix 
D.    
Population 
 The project was comprised of a primary and secondary population.  The primary 
population consisted of the providers in the organization, four physicians and four nurse 
practitioners (NP).  The providers considered for the project were part of the organization during 
both audit periods.  The participants were contacted in person, prior to the education and 
feedback intervention for recruitment.  A recruitment and consent form was signed before 
initiating the chart audit process.  Providers were not required to participate as a job requirement, 
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and their performance measures did not impact their employment.  The letter of support 
(Appendix D) from the organization is included. 
The secondary population will consist of patients 65 years and older (Table 1).  Exclusion 
criteria will consist of individuals new to the practice after the intervention period. 
Nath, Costigan & Hsia (2016) indicated that individuals attending FQHC are low income, 
young, uninsured or Medicaid-insured, and from racial and ethnic minorities.  Data for the City 
of Richmond shows that in 2017, 11.5% of the population was over the age of 65 years of age, 
44.2% are white, and 48.6% are African American, and 25.4% of the population live in poverty 
(United States Census Bureau, 2017). 
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Table 1.   
Demographic information for patients over the age of 65 years of age. 
All 1001 
Gender 
Male 
Female 
 
403 
598 
Race 
American Indian or Alaskan Native 
Asian 
Native Hawaiian or other Pacific 
Black or African American 
White 
Other 
Other Pacific Islander 
Unreported/Refused to report 
More than one race 
 
3 
31 
1 
707 
160 
63 
1 
32 
0 
Ethnicity 
Hispanic/Latino 
Non-Hispanic /Latino 
Refused to report 
 
56 
931 
11 
Insurance 
Medicare Managed Care 
Medicare Non-Managed Care 
 
144 
368 
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Medicaid Managed Care 
Medicaid Non-Managed Care 
Other public payors non-managed 
Private non-managed care 
17 
4 
102 
90 
Note. Patient demographics.  Characteristics of patients over the age of 65 years seen in the 
FQHC between 01/01/2018 and 06/30/2018. 
Ethical Considerations  
 The intervention was started after being approved by the lead institution Institutional 
Review Board (IRB) (Appendix B).  The project leader also obtained a letter of support from the 
CMO (Appendix D), and a letter from the human resource department approving the project and 
indicating that participants will not be required to participate as a job requirement, and their 
performance measures will not impact their employment (Appendix E).  The project leader 
included the certificate from the Collaborative Institutional Training Initiative (CITI) indicating 
completion of human research training (Appendix C).   
Confidentiality was maintained at every step of the project.  The reports did not include 
patients’ identifiers.  Data from the pre-and post-intervention was kept in computer files.  The 
information was password protected and only accessible by the project leader.  Electronic files 
were backed up regularly, and copies kept with the questionnaires.  The questionnaire results 
were stored in a safe and secure location, a locked cabinet only accessible by the project leader.  
A master list (Appendix K) was being used to protect the provider’s privacy.  All the data 
collected will be store for three years, after this time, electronic data will be deleted using 
software designed to remove all data from the storage device.  Hard copies will be shredded and 
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recycled.  The disposal of the data will be documented indicating how and when it was 
completed.   
Data Collection 
 Data collection took place at two points in time, pre-and post-intervention, 30 days apart.  
Data collection for the pre-intervention period was done in the same period the previous year.  
The reports were run by the project leader and recorded utilizing the provider identification 
(Appendix K) list and the chart audit form (Appendix J).  The chart audit was done pre-and post-
intervention as well.  The project leader audited up to 15 charts for patients over the age of 65 
years, selecting the first 15 charts.  If a provider did not see that many patients in the secondary 
population, the audit was done in all patients seen.  The chart audit (Appendix I) will include 
documentation for pneumococcal vaccines: 
 Prevnar 13 
 Pneumovax 23 
 Historical immunization Prevnar 13 
 Historical immunization Pneumovax 23 
 Education provided 
 Refused by patient 
Tools 
 The organization uses E-Clinical Works (ECW) as the EMR, reports, and charts were 
obtained from this application.  The audit process was handled via chart review and results 
secured in an electronic file.  The feedback process is more effective when is the data is 
delivered verbally by a trusted source, and the feedback is anchored in an overarching quality 
improvement structure (Agency for Healthcare Research and Quality [AHRQ], 2017).  The 
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feedback report was “provider friendly” and included the following components to improve 
effectiveness: 
 Actual performance is displayed 
 Reports are accompanied by a specific improvement plan that facilitates goal 
achievement, in this case, the educational intervention 
 The report format facilitates correct interpretation and highlights important patterns in 
performance (AHRQ, 2017). 
The Continuing Professional Development (CPD) reaction questionnaire (Appendix G) is 
a tool to assess the impact of CPD activities on clinical practice (Légaré et al., 2011; Légaré et 
al., 2014, Légaré et al., 2017).  This questionnaire shows adequate validity and reliability, the 
Cronbach’s coefficients are 0.77 to 0.85 (Légaré et al., 2017; Légaré et al., 2014).  The 
questionnaire is a 12-item integrated model, combining social cognitive theories for explaining 
healthcare providers’ clinical behaviors through the proxy of intention (Légaré et al., 2017).    
The questionnaire proposes three categories (a) intention to adopt a particular behavior, (b) belief 
about their capabilities, and (c) past behavior and habits (Légaré et al., 2017).  The CPD reaction 
questionnaire is published with permission to use (Université Laval, 2013).  The generic CPD 
questionnaire was adapted by replacing the word “behavior” in each item with “prescribe 
pneumococcal vaccine.”  The items in the questionnaire are precoded with Likert-type scale 
values (Table 2) (Légaré et al., 2017).  The item score ranges from one to seven with assigned 
values, strongly disagree=1, strongly agree=7; never=1, always=7 (Légaré et al., 2017) 
(Appendix H). 
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Table 2.   
Summary of CPD-Reaction questionnaire scores on items and constructs. 
 
Note.  CPD-Reaction questionnaire score table was retrieved from Légaré, F., Freitas, A., 
Trucotte, S., Bourdas, F., Jacuques, A., Luconi, F., …Labrecque, M.  (2017).  Responsiveness of 
a simple tool for assessing change in behavioral intention after continuing professional 
development activities.  PLos, One, 12(5), e0176678.  doi: 10.1371/journal.pone.0176678 
 
Intervention 
Pre-intervention. 
 The preconception of the project originated from conversations with other providers who 
acknowledged the gap in preventive services related to pneumococcal vaccines in the 
older population of the center.   
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 In May 2018, the project leader consulted with the CMO regarding the implementation of 
a scholarly project to increase the rate of pneumococcal vaccines in patients over the age 
of 65 years.   
 The CMO verbally agreed to the project and produced a letter of support (Appendix D). 
 A preliminary report was requested from the IT department to determined rates of 
pneumococcal vaccination for adults over 65 years of age between January 1, 2018, and 
June 30, 2018.  This information was used when discussing the initiative and needs 
assessment in care.   
 The recruitment process took place before the initiation of the chart audit process at each 
provider’s office.  Providers willing to participated signed a consent form (Appendix L).        
 The educational intervention was conducted via a presentation where the project leader 
visited the different clinics on a selected day to engage with the providers and complete 
the intervention. 
 The information for this presentation includes current pneumococcal vaccination rates 
and recommendation by the CDC, the IDSA and the ATS (Mandell et al., 2007).  
 A chart audit was completed before the educational intervention to identify current 
practices by providers, feedback of these results was included in the educational session 
along with current guidelines. 
Intervention. 
 This stage of the process was grounded in the educational intervention to increase 
awareness of the current status of pneumococcal vaccination and the need to improve 
preventive services.   
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 The presentation took place at each office; the project leader met with the providers and 
presented the information, in verbal and written form. 
 After the educational intervention, the providers completed the CPD reaction 
questionnaire. 
Post-intervention.   
 After the intervention was completed, the project leader began the data analysis.  
 The analysis focused on the effectiveness of this intervention and future applicability and 
sustainability if successful.  
 Once data was analyzed, results evaluated and implication determined, the dissemination 
process began.   
 Project results were shared with providers and the CMO.  Individual provider’s measures 
were not shared with the organization or other providers.   
 Each provider received a report with their vaccination rate for self-assessment. 
Data Analysis  
Pneumococcal vaccination rate in the organization.  The data analysis for this 
outcome was completed by comparing the pneumococcal vaccination rate before and after the 
intervention.  The data obtained from the chart review and the EMR report included (a) number 
of patients with documented pneumococcal vaccine in the chart, either PCV13 or PPSV23, (b) 
number of patient with a documented history of receiving either PCV13 or PPSV23, (c) number 
of patient receiving PNA vaccine education, and (d) number of patients refusing to receive the 
vaccine.  This data allowed analyzing the impact of the intervention in the ordering and 
administering of the vaccine. 
PNEUMOCOCCAL IMMUNIZATION IN OLDER ADULTS  33 
 
Pneumococcal vaccination rate for each provider.  The data analysis for this outcome 
was completed by comparing the pneumococcal vaccination rate before and after the intervention 
for each provider’s panel.  The data obtained from the chart review and the EMR report included 
(a) number of patients with documented pneumococcal vaccine in the chart, either PCV13 or 
PPSV23, (b) number of patient with a documented history of receiving either PCV13 or 
PPSV23, (c) number of patient receiving PNA vaccine education, and (d) number of patients 
refusing to receive the vaccine.  
Provider intent to change and improve their practice based on the interventions.  
The data analysis for this outcome was completed by analyzing the results of the CPD 
questionnaire.  This information determined if the chart review, feedback, and educational 
intervention precipitated a change in practice with PNA vaccination. 
SECTION FOUR: RESULTS 
 This section presents the results of the data analysis, including the qualitative analysis of 
the chart audit results and the CPD questionnaire.  The demographic data is described for the 
primary population.  Key findings are highlighted based on the project outcomes. 
 The primary population consisted of eight providers (n=8), four physicians and four NPs, 
in the pre- and post-intervention periods.  The sample size for the secondary population pre-
intervention was n=96 patients, while post-intervention was n=120 patients.  The chart audit pre-
intervention was completed between December 4, 2017, and January 4, 2018.  The chart audit 
post-intervention was completed between December 4, 2018, and January 4, 2019.  One provider 
left the practice before the intervention took place.  The CPD questionnaire was completed by 
providers on December 3, 2018, the same day the intervention took place.  A total of eight 
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participants (n=8) completed the CPD questionnaire after the educational intervention, with a 
response rate of 100%.  One questionnaire had three answers not selected with a comment noted. 
Objective One: Increase Aggregate Pneumococcal Vaccination Rate 
 The documented pneumococcal vaccination rate pre-intervention in the organization was 
n=2, with Prevnar (n=1) and Pneumovax (n=1) vaccines documented as given during this time 
frame (Figure 1).  The documented vaccination rate of historical pneumococcal vaccine was 
n=20 (Figure 2).  From this group, Prevnar (n=6) and Pneumovax (n=14) were received the 
vaccines in the past.  
 The post-intervention audit shows n=13 individuals received a pneumococcal vaccine 
during the post-intervention period (Figure 1).  From this population, Prevnar (n=10) and 
Pneumovax (n=3) were received during the post-intervention period.  The documented 
vaccination rate of historical pneumococcal vaccine was n=36 (Figure 2).  From this group, 
Prevnar (n=15) and Pneumovax (n=21) were documented as received in the past.   
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Figure 1.   Pneumococcal vaccines documented pre- and post-intervention. 
 
 
Figure 2.  Historical pneumococcal vaccines documented pre- and post-intervention. 
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Objective Two: Increase Individual Pneumococcal Vaccination  
 The individual outcome showed that four providers (n=4) increased the administration of 
pneumococcal vaccines in the post-intervention period.  The other four providers (n=4) maintain 
the same rates.  These providers did not provide vaccination during the pre- and post- 
intervention periods.  The historical vaccination rates were increased in five of the providers 
(n=4) while two providers (n=2) maintain the same rates pre- and post-intervention.  One 
provider (n=1) decreased the historical vaccination rate. 
Objective Three: Provider Intent to Change and Improve their Practice Based on the 
Interventions   
 The CPD questionnaire offers insight into the provider’s intent to change and improve 
their practice based on the intervention provided.  This questionnaire measures construct answers 
on a Likert-type scale, with scores ranging from one to seven with assigned values, strongly 
disagree=1, strongly agree=7; never=1, always=7.  Mean scores above the midpoint reflect more 
favorable whereas those below the midpoint are less-favorable.  One provider did not answer 
questions two, six and nine; instead, the provider wrote a sentence.  Other scores from this 
provider are included in the data analysis and evaluation.  The intention construct showed a score 
of 7, indicating a strong intent to change practice.  The social influence construct yielded a score 
of 3.75 indicating low social influence in the ordering of pneumococcal vaccines in individual 
practice.  The construct related to belief about capabilities showed a score of 6.83, representing a 
strong belief in the individual’s capability to order pneumococcal vaccines.  The moral norm 
construct displayed a score of 6.93, indicating strong moral reasoning on the needs of the 
vaccine.  Moreover, finally, the construct belief about consequence was 7, showing a strong 
sense of the pneumococcal vaccine being useful and beneficial. 
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SECTION FIVE: DISCUSSION 
 This project sought to increase the rate of pneumococcal vaccine in a FQHC by 
implementing a chart audit and provider educational intervention.  The project also aimed at 
assessing the provider’s intent to prescribe more pneumococcal vaccines through the use of a 
questionnaire.  It was established that pneumococcal bacteria could cause mild to severe illness, 
but it could also be deadly for adults over the age of 65 years of age, individuals with chronic 
conditions, and immunocompromised (CDC, 2017a). 
Implication for Practice 
 The project showed an increase in pneumococcal vaccines provided to patients pre- and 
post-intervention (n=2, n=13 respectively). There was a noticeable increase in vaccination rates 
in three providers.  Although the vaccination rate did not reach a goal of 100%, it is important to 
mention that an increase in vaccination can significantly impact the population.  Even though 
herd immunity limits the transmission of the bacteria, specific populations like the one described 
in the project, do not intrinsically achieve excellent anti pneumococcal response (Berical, Harris, 
Cruz, Possick & Dela Cruz, 2016), evidencing the need for effective vaccination in the adult over 
65 years of age population. 
 There was also an increase in historical vaccination between the pre- and post-
intervention periods (n=20, n=36 respectively).  It is unclear at this point and with the 
information collected the vaccination dates.  It is possible that providers, who were aware of the 
project, were prescribing the vaccines due to their knowledge before the intervention.  
Regardless of the administration date, the patients benefited from an increase in vaccination.  It 
is important to take under consideration for further research, the intervals between both vaccines, 
Prevnar and Pneumovax since CDC guidelines are very specific.  The impetus to use Prevnar in 
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the elderly population was based on robust immunogenicity data and supported by the CAPiTA 
project (Berical et al., 2016). It is important to consider also, that as life expectancy continues to 
increase, this population will need to achieve vaccine efficacy in cases known to wane over time 
project (Berical et al., 2016) creating concerns for future public health demands. 
 The sample size from the pre- and post-intervention were noticeable different (n=96, 
n=120, respectively).  In this case, some providers did not get to see 15 patients in the selected 
secondary population in the selected timeframe.  This matter could have played a part in the 
lower rates noted pre-intervention.   
 Similar to research findings, vaccine provision was a strong predictor of individuals 
receiving the vaccine (Schneeberg et al., 2014).  Providers documented educating patients on the 
importance of the vaccine and, in cases where the pneumococcal vaccine was not available, 
education was provided to receive the vaccine on the next office visit.  This problem was noted 
in one of the CPD questionnaires, where one provider instead of answering questions five, 
indicated that the vaccine is easy to order but “the problem sometimes is getting it.”  This issue 
can be addressed in the sustainability section, where an increment in vaccines ordered can be 
addressed based on vaccines administered.  Regardless of these problems, research shows that 
recommendation from a healthcare provider is a strong predictor of vaccination (Schneeberg et 
al., 2014) and the patient should be encouraged to receive the vaccines in the office or the 
pharmacy, and this should be documented. 
 The CPD questionnaire provided information on the intent to change practice based on 
the interventions provided.  The results of the questionnaire provided positive feedback on the 
intervention, indicating a strong desire to order more pneumococcal vaccines.  As mentioned 
previously, one provider did not answer three questions.  Two of these questions belong to the 
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social influence construct, creating a lower than expected score.  The third question was included 
in the beliefs about capacity construct, also lowering this score.  Given this information, the 
results in these two categories will need to be evaluated separately.   
The process of audit and feedback was successful in increasing the rate of pneumococcal 
vaccine in adults over the age of 65 years.  This strategy was implemented to increase 
compliance with desire practice and improve patient outcomes (Ivers et al., 2012).  A strong 
organizational structure and culture focused on quality improvement, and feedback can assist in 
professional behavioral changes (Ivers et al., 2012) by impacting the quality of care provided. 
The project had several limitations.  First, the pre-intervention sample size (n=96) was 
significantly smaller than the post-intervention sample size (n=120).  Second, participants were 
recruited from a convenient sample, lacking randomization.  Third, the project was conducted in 
one FQHC with limited generalizability.  Four, the lack of vaccines in some locations could have 
hindered the capacity of the patient from receiving the vaccine.  Last, the limited time for the 
educational intervention and feedback to providers could have an impact on the provider’s 
enthusiasm and participation. 
Sustainability 
The sustainability plan to continue the practice change is influenced by the interest of the 
senior management and individual providers.  The successful implementation of this project can 
encourage the CMO to include pneumococcal vaccination as an outcome measure being tracked 
on the provider’s meetings at least every quarter.  The National Committee for Quality 
Assurance (NCQA) has a measure to improve processes, in this case, the National Quality 
Strategy Domain: Community/Population Health measures the Pneumococcal Vaccination Status 
for Older Adults.  Measures from NCQA are used by FQHC for patient-center medical homes 
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(PCMH) and Health Resources and Services Administration (HRSA) initiatives.  One of the 
main concerns is feasibility.  The convenience of pneumococcal vaccination is in having the 
necessary supplies in hand to offer patients the vaccine while they are in the office.  This can be 
challenging from a logistic standpoint due to the number of offices within the FQHC.  The 
organization and selected personnel need to be proactive on the vaccines ordering process and 
have a delegated person to address the needs in the different offices.  Offering and ensuring 
patients are vaccinated is a cultural change within an organization.  Any nursing staff member 
can perform this task.  The sustainability plan can also include nurses assessing if a vaccine was 
received or if it is needed and documenting it in the patient’s chart.    This task can be addressed 
during the flu season when asking the patient if they would like to receive both vaccines, 
influenza and pneumococcal. 
Dissemination Plan  
 The dissemination of the project results took several steps.  First, providers were met 
individually and provided with a post-intervention feedback report.  This report incorporated the 
pre- and post-intervention vaccination rates individually and aggregate.  This printed report was 
given to each provider to keep.  The aggregate results were also discussed in the monthly 
provider’s meeting.  A discussion of the project took place, guided by the CMO and feedback 
was presented to improve future endeavors. 
 Other nursing staff also became part of the audience for the dissemination plan.  The 
morning huddle meetings were selected to report the project results.  This aimed at incorporating 
the organization in the project and a step in the direction of cultural change.  No written 
information was provided, but a verbal report of the improvement in pneumococcal vaccination 
was given. 
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Pneumococcal disease is a potential healthcare concern that could be prevented with the 
use of recommended vaccinations.  Focusing on the pneumococcal vaccination rate in the FQHC 
addresses a cultural change to advance patient and provider outcomes.  The use of a chart audit, 
provider education, and feedback were successful at increasing the knowledge and the intent to 
change and improve clinical practice, as well as significantly impacting the health of the 
community. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PNEUMOCOCCAL IMMUNIZATION IN OLDER ADULTS  42 
 
REFERENCES 
Agency for Healthcare Research and Quality. (2017). Confidential physician feedback reports: 
Designing for optimal impact on performance.  Retrieved from 
https://www.ahrq.gov/sites/default/files/publications/files/confidreportguide_1.pdf 
American Lung Association. (2010). Missed opportunities: Influenza and pneumonia 
vaccination in older adults.  Retrieved from 
http://www.lung.org/assets/documents/research/adult-vaccination-disparities.pdf 
Baldo, V., Cocchio, S., Gallo, T., Furlan, P., Romor, P., Bertoncello, C., & ... Baldovin, T. 
(2016). Pneumococcal conjugated vaccine reduces the high mortality for community-
acquired pneumonia in the elderly: An Italian regional experience. Plos ONE, 11(11), 1-
11. doi:10.1371/journal.pone.0166637 
Berical, A. C., Harris, D., Cruz, C. S. D., Possick, J. D., & Dela Cruz, C. S. (2016). 
Pneumococcal vaccination strategies: An update and perspective. Annals of the American 
Thoracic Society, 13(6), 933–944. https://doi-
org.ezproxy.liberty.edu/10.1513/AnnalsATS.201511-778FR 
Brown, C. G. (2014). The Iowa Model of Evidence-Based Practice to promote quality care: An 
illustrated example in oncology nursing. Clinical Journal Of Oncology Nursing, 18(2), 
157-159. doi:10.1188/14.CJON.157-159 
Brown, J. D., Harnett, J., Chambers, R., & Sato, R. (2018). The relative burden of community-
acquired pneumonia hospitalizations in older adults: A retrospective observational study 
in the United States. BMC Geriatrics, 18(1), 92. doi:10.1186/s12877-018-0787-2 
PNEUMOCOCCAL IMMUNIZATION IN OLDER ADULTS  43 
 
Cafiero-Fonseca, E. T., Stawasz, A., Johnson, S. T., Sato, R., & Bloom, D. E. (2017). The full 
benefits of adult pneumococcal vaccination: A systematic review. Plos ONE, 12(11), 1-
23. doi:10.1371/journal.pone.0186903 
Capital Area Health Network. (2018). Welcome to Capital Area Health Network.  Retrieved from 
https://cahealthnet.org/about/ 
Center for Disease Control and Prevention. (n.d.). Morbidity and mortality weekly report 
(MMWR).  Retrieved from 
https://wonder.cdc.gov/mmwr/mmwr_2016_38.asp?mmwr_year=2016&mmwr_week=39
&mmwr_table=4A&request=&mmwr_location=Richmond,%20Va 
Center for Disease Control and Prevention. (2005). Trends in causes of death among older 
persons in the United States.  Retrieved from 
https://www.cdc.gov/nchs/data/ahcd/agingtrends/06olderpersons.pdf 
Center for Disease Control and Prevention. (2017a). Pneumococcal vaccination.  Retrieved from 
https://www.cdc.gov/vaccines/vpd/pneumo/hcp/index.html 
Center for Disease Control and Prevention. (2017b). Adults: Protect yourself with pneumococcal 
vaccines.  Retrieved from https://www.cdc.gov/features/adult-pneumococcal/index.html 
Colquhoun, H. L., Brehaut, J. C., Sales, A., Ivers, N., Grimshaw, J., Michie, S., & ... Eva, K. W. 
(2013). A systematic review of the use of theory in randomized controlled trials of audit 
and feedback. Implementation Science, 8(1), 1-8. doi:10.1186/1748-5908-8-66 
Deursen, A. M. M. van, Houten, M. A. van, Webber, C., Patton, M., Scott, D., Patterson, S., … 
Grobbee, D. E. (2018). The Impact of the 13-Valent Pneumococcal Conjugate Vaccine 
on Pneumococcal Carriage in the Community Acquired Pneumonia Immunization Trial 
PNEUMOCOCCAL IMMUNIZATION IN OLDER ADULTS  44 
 
in Adults (CAPiTA) Study. Clinical Infectious Diseases, 67(1), 42–49. https://doi-
org.ezproxy.liberty.edu/10.1093/cid/ciy009 
Drijkoningen, J.C. & Rohde, G U. (2014). Pneumococcal infection in adults: Burden of disease.  
Clinical Microbiology and Infection, 20, 545-51.  doi: 10.1111/1269-0691.12461 
Harris, A. D., McGregor, J. C., Perencevich, E. N., Furuno, J. P., Zhu, J., Peterson, D. E., & 
Finkelstein, J. (2006). The use and interpretation of quasi-experimental studies in medical 
informatics. Journal of the American Medical Informatics Association: JAMIA, 13(1), 
16–23. http://doi.org/10.1197/jamia.M1749 
Iowa Model Collaborative. (2017). Iowa model of evidence-based practice: Revisions and 
validation.  Worldviews on Evidence-based Nursing, 14(3), 175-182. 
doi:10.111/wvn.12223 
Ivers, N., Jamtvedt, G., Flottorp, S., Young, J. M., Odgaard-Jensen, J., French, S. D., & ... 
Oxman, A. D. (2012). Audit and feedback: Effects on professional practice and 
healthcare outcomes. The Cochrane Database Of Systematic Reviews, (6), CD000259. 
doi:10.1002/14651858.CD000259.pub3 
Ivers, N. M., Grimshaw, J. M., Jamtvedt, G., Flottorp, S., O'Brien, M. A., French, S. D., & ... 
Odgaard-Jensen, J. (2014). Growing literature, stagnant science? Systematic review, 
meta-regression and cumulative analysis of audit and feedback interventions in health 
care. Journal Of General Internal Medicine, 29(11), 1534-1541. doi:10.1007/s11606-
014-2913-y 
Falkenhorst, G., Remschmidt, C., Harder, T., Hummers-Pradier, E., Wichmann, O., & Bogdan, 
C. (2017). Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) 
PNEUMOCOCCAL IMMUNIZATION IN OLDER ADULTS  45 
 
against pneumococcal disease in the elderly: Systematic review and meta-analysis. Plos 
ONE, 12(1), 1-18. doi:10.1371/journal.pone.0169368 
Huss, A., Scott, P., Stuck, A. E., Trotter, C., & Egger, M. (2009). Efficacy of pneumococcal 
vaccination in adults: a meta-analysis. CMAJ: Canadian Medical Association 
Journal, 180(1), 48-58. 
Legare F, Borduas F, Jacques A, Laprise R, Voyer G, Boucher A, Luconi F, Rousseau M, 
Labrecque M, Sargeant J, Grimshaw J, Godin G (2011) Developing a theory-based 
instrument to assess the impact of continuing professional development activities on 
clinical practice: A study protocol. Implement Science. 
Légaré F, Borduas F, Freitas A, Jacques A, Godin G, Luconi F, Grimshaw J and the CPD‐ KT 
team (2014) Development of a simple 12-item theory-based instrument to assess the 
impact of continuing professional development on clinical behavioral intentions. PLoS 
ONE 9(3): e91013. doi:10.1371/journal.pone.0091013. 
Légaré, F., Freitas, A., Trucotte, S., Bourdas, F., Jacuques, A., Luconi, F., …Labrecque, M.  
(2017).  Responsiveness of a simple tool for assessing change in behavioral intention 
after continuing professional development activities.  PLos, One, 12(5), e0176678.  doi: 
10.1371/journal.pone.0176678 
Mandell, L. A., Wunderink, R. G., Anzueto, A., Bartlett, J. G., Campbell, G. D., Dean, N. C., & 
... Whitney, C. G. (2007). Infectious Diseases Society of America/American Thoracic 
Society consensus guidelines on the management of community-acquired pneumonia in 
adults. Clinical Infectious Diseases: An Official Publication Of The Infectious Diseases 
Society Of America, 44 Suppl 2S27-S72. 
PNEUMOCOCCAL IMMUNIZATION IN OLDER ADULTS  46 
 
Mangen, M. J., Huijts, S. M., Bonten, M. M., & de Wit, G. A. (2017). The impact of community-
acquired pneumonia on the health-related quality-of-life in elderly. BMC Infectious 
Diseases. doi:10.1186/s12879-017-2302-3 
Nath JB, Costigan S, Hsia RY. (2016). Changes in demographics of patients seen at Federally 
Qualified Health Centers, 2005-2014. JAMA Intern Med. 176(5), 712–714. 
doi:10.1001/jamainternmed.2016.0705 
Nowalk, M. P., Nolan, B. D., Nutini, J., Ahmed, F., Albert, S. M., Susick, M., & Zimmerman, R. 
K. (2014). Success of the 4 pillars toolkit for influenza and pneumococcal vaccination in 
adults. Journal For Healthcare Quality: Promoting Excellence In Healthcare, 36(6), 5-
15. doi:10.1111/jhq.12020 
Park, N. J., Sklaroff, L. M., Gross-Schulman, S., Hoang, K., Tran, H., Campa, D., & ... 
Guterman, J. J. (2016). Innovative strategies designed to improve adult pneumococcal 
immunizations in safety net patient-centered medical homes. Population Health 
Management, 19(4), 240-247. doi:10.1089/pop.2015.0099 
Remschmidt, C., Harder, T., Wichmann, O., Bogdan, C., & Falkenhorst, G. (2016). 
Effectiveness, immunogenicity, and safety of 23-valent pneumococcal polysaccharide 
vaccine revaccinations in the elderly: A systematic review. BMC Infectious Diseases.  
doi:10.1186/s12879-016-2040-y 
Schaffer, M. A., Sandau, K. E., & Diedrick, L. (2013). Evidence-based practice models for 
organizational change: Overview and practical applications. Journal Of Advanced 
Nursing, 69(5), 1197-1209. doi:10.1111/j.1365-2648.2012.06122.x 
Schneeberg, A., Bettinger, J. A., McNeil, S., Ward, B. J., Dionne, M., Cooper, C., & ... Halperin, 
S. A. (2014). Knowledge, attitudes, beliefs, and behaviors of older adults about 
PNEUMOCOCCAL IMMUNIZATION IN OLDER ADULTS  47 
 
pneumococcal immunization, a Public Health Agency of Canada / Canadian Institutes of 
Health Research Influenza Research Network (PCIRN) investigation. BMC Public 
Health, 14(1), 1-16. doi:10.1186/1471-2458-14-442 
Tuti, T., Nzinga, J., Njoroge, M., Brown, B., Peek, N., English, M., & ... van der Veer, S. N. 
(2017). A systematic review of electronic audit and feedback: Intervention effectiveness 
and use of behaviour change theory. Implementation Science. doi:10.1186/s13012-017-
0590-z 
United States Census Bureau.  (2017).  Quick facts Richmond City, Virginia.  Retrieved from 
https://www.census.gov/quickfacts/fact/table/richmondcityvirginia/PST040217 
Université Laval.  (2013).  A theoRy-basEd instrument to assess the impACT of continuing 
professional development activities on professional behavIOr chaNge The CPD Reaction 
Questionnaire.  Retrieved from 
https://ktcanada.ohri.ca/costars/Research/docs/CPD_Questionnaire.pdf 
Vila-Corcoles, A., & Ochoa-Gondar, O. (2013). Preventing pneumococcal disease in the 
elderly. Drugs & Aging, 30(5), 263-276. doi:10.1007/s40266-013-0060-5 
Virginia Commonwealth University Health. (n.d.). Virginia Coordinated Care Program.  
Retrieved from https://www.vcuhealth.org/vcu-medical-center/billing-and-
insurance/financial-assistance/virginia-coordinated-care-program 
 
 
 
 
 
 
 
PNEUMOCOCCAL IMMUNIZATION IN OLDER ADULTS  48 
 
APPENDICES 
Appendix A 
Evidence Table 
Name: Mara Dominguez 
Clinical Question: In providers working at an FQHC (P), how does an educational intervention providing evidence-based information 
on pneumococcal immunizations (I), addresses pneumococcal vaccination in older adults (O)? 
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J., Huijts, S. 
M., Bonten, 
M. M., & de 
Wit, G. A. 
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the difference 
in health-
related quality 
of life of 
Cost, Health 
status and 
Outcomes of 
CAP (CHO-
CAP) was 
A matched 
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prospective 
randomized, 
The one-year 
quality-
adjusted life 
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health-related 
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cohort study. 
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support a 
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(2017). The 
impact of 
community-
acquired 
pneumonia on 
the health-
related 
quality-of-life 
in 
elderly. BMC 
Infectious 
Diseases, 171
elderly with 
and without 
community-
acquired 
pneumonia 
(CAP) during 
a 12-month 
period. 
executed 
parallel to the 
Community-
Acquired 
Pneumonia 
Immunization 
trials in 
Adults 
(CAPiTA).   
CAPiTA 
participants 
were 
double-blind 
placebo-
controlled 
trial 
evaluating the 
effectiveness 
of a 13-valent 
pneumococcal 
vaccine in 
individuals 
older than 65 
years of age.  
quality of life 
were lower 
for CAP 
patients.  
Mortality in 
the follow-up 
year was 
8.4% for CAP 
patients and 
1.2% for non-
diseased 
people. 
participants 
were willing 
to participate 
versus non-
responding 
CAP patients. 
combination 
with the 
CAPiTA 
results to 
provide a 
more 
comprehensiv
e 
understanding 
of 
immunization
s. 
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approached at 
the time of 
vaccination to 
participate in 
the CHO-
CAP study.  
Health-related 
quality of life 
was assessed 
in 562 
individuals 
hospitalized 
Health-related 
quality of life 
was 
determined 
one to two 
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12 months 
after that.  
One year 
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unaffected 
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sex, and 
health status. 
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adjusted life 
years were 
estimated for 
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Baldo, V., To examine Individuals 65 Retrospective The one-year Level 4. Limitations The 
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Cocchio, S., 
Gallo, T., 
Furlan, P., 
Romor, P., 
Bertoncello, 
C., & ... 
Baldovin, T. 
(2016). 
Pneumococcal 
Conjugated 
Vaccine 
Reduces the 
the role of 
anti-
pneumococcal 
vaccination as 
a factor 
associated 
with 
pneumonia-
related 
mortality at 
one year. 
years old and 
older 
hospitalized 
with CAP 
were enrolled 
in their first 
hospitalizatio
n.  4766 
individuals 
were 
identified, 
after 
observational 
cohort study.  
Individuals 
were assigned 
to three 
groups: Not 
vaccinated, 
PPV23 and 
PCV13.  
Patients were 
followed up at 
one year and 
survival rate 
after 
hospitalizatio
n was 83.6% 
in the 
unvaccinated 
group, 85.9% 
in the PPV23 
group and 
89.3% in the 
PVC12 group.  
The risk of 
include (a) 
small sample 
for the PCV13 
vaccine group 
and (b) 
hospital 
discharge 
records 
lacking 
microbiology 
data. 
information 
supports the 
use of OVC 
13 as a 
protective 
agent against 
pneumococcal 
disease. 
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High 
Mortality for 
Community-
Acquired 
Pneumonia in 
the Elderly: 
an Italian 
Regional 
Experience. P
los 
ONE, 11(11), 
1-11. 
exclusion 
criteria, 4030 
participants 
were divided 
into three 
groups. 
the outcome 
investigated 
was mortality. 
death to 
pneumonia 
increase with 
age, shorter 
hospital stay, 
and male 
gender. 
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doi:10.1371/j
ournal.pone.0
166637 
 
Falkenhorst, 
G., 
Remschmidt, 
C., Harder, T., 
Hummers-
Pradier, E., 
Wichmann, 
O., & 
To evaluate 
the efficacy 
and 
effectiveness 
of PPV23 
against 
invasive 
pneumococcal 
Search 
pertinent 
clinical trials 
and 
observational 
studies in 
databases 
MEDLINE, 
Systematic 
review and 
meta-analysis, 
using the 
Cochrane 
Risk for Bias 
tool and the 
Newcastle-
Significant 
vaccine 
effectiveness/
efficacy of 
PPV23 
against 
invasive 
pneumococcal 
Level 1: 
systematic 
review and 
meta-analysis. 
Limitations 
include (a) 
use of only 
two random 
clinical trials 
in a specific 
population in 
Japan, (b) 
The 
information 
will be used 
to support 
PPV23 use in 
clinical 
practice and 
the project. 
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Bogdan, C. 
(2017). 
Effectiveness 
of the 23-
Valent 
Pneumococcal 
Polysaccharid
e Vaccine 
(PPV23) 
against 
Pneumococcal 
Disease in the 
disease and 
pneumococcal 
pneumonia in 
adults older 
than 60 years 
of age living 
in 
industrialized 
countries. 
EMBASE, 
Cochrane 
Central 
Register of 
Controlled 
Trials, and 
Cochrane 
Database of 
Systematic 
Reviews.  
1199 articles 
were 
Ottawa Scale, 
quality rated 
using the 
GRADE 
criteria. 
disease and 
pneumococcal 
pneumonia by 
any serotype 
in the elderly.  
This is 
comparable to 
the efficacy of 
PVC13 
against 
vaccine-
serotype 
wide 
confidence 
interval 
around the 
pooled 
vaccine 
effectiveness/
efficacy, and 
(c) available 
data is 
insufficient to 
determine the 
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Elderly: 
Systematic 
Review and 
Meta-
Analysis. Plos 
ONE, 12(1), 
1-18. 
doi:10.1371/j
ournal.pone.0
169368 
 
identified, 17 
studies were 
analyzed. 
disease in the 
recent clinical 
trial. 
duration of 
protection 
provided by 
PPV23. 
Cafiero- To assess the 5857 articles Systematic Most studies Level 1. Limitations I would use 
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ics of the 
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Methods 
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Level of 
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Support a 
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Fonseca, E. 
T., Stawasz, 
A., Johnson, 
S. T., Sato, 
R., & Bloom, 
D. E. (2017). 
The full 
benefits of 
adult 
pneumococcal 
vaccination: 
A systematic 
extent to 
which 
literature has 
empirically 
captured the 
benefits of 
adult 
pneumococcal 
vaccines. 
were 
identified, and 
150 articles 
were 
analyzed.  
Eligibility 
criteria and 
PICO criteria 
were 
described. 
review and 
meta-analysis. 
Researchers 
reviewed 
PubMed and 
Embase for 
articles 
regarding the 
full benefits 
of adult 
pneumococcal 
immunization, 
indicated 
health 
benefits and 
cost savings.  
The studies 
focusing on 
PVC13 deal 
more with 
economic 
benefits. 
include (a) 
English-only 
studies, (b) 
inability to 
use tools to 
determine 
bias, and (c) 
other 
vaccinations 
can affect the 
potential 
benefits of the 
this 
information to 
support 
change 
because it 
provides 
additional 
data 
supporting the 
benefits of the 
vaccine.  
PNEUMOCOCCAL IMMUNIZATION IN OLDER ADULTS  58 
 
Article Title, 
Author, etc. 
(Current 
APA 
Format) 
Study 
Purpose 
Sample 
(Characterist
ics of the 
Sample: 
Demographic
s, etc.) 
Methods 
Study 
Results 
Level of 
Evidence 
(Use Melnyk 
Framework) 
Study 
Limitations 
Would Use as 
Evidence to 
Support a 
Change? 
(Yes or No) 
Provide 
Rationale. 
review. Plos 
ONE, 12(11), 
1-23. 
doi:10.1371/j
ournal.pone.0
186903 
 
a list of 
benefits was 
also provided. 
pneumococcal 
vaccine. 
Remschmidt, 
C., Harder, T., 
Wichmann, 
O., Bogdan, 
C., & 
To 
systematically 
assess the 
effectiveness 
and safety of 
1164 articles 
were 
identified, and 
14 were 
analyzed. 
A systematic 
review in 
MEDLINE, 
EMBASE and 
Cochrane 
None of the 
studies 
reported on 
effectiveness.  
Immunogenici
Level 1. Limitations 
include (a) 
difficulty 
interpreting 
data due to 
I would 
consider this 
information as 
evidence to 
support 
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Falkenhorst, 
G. (2016). 
Effectiveness, 
immunogenici
ty, and safety 
of 23-valent 
pneumococcal 
polysaccharid
e vaccine 
revaccinations 
in the elderly: 
a systematic 
PPSV23 
revaccination. 
Central 
Register of 
Controlled 
Trials.  
Articles 
compared the 
effectiveness, 
immunogenici
ty, and safety 
of PPSV23 as 
a primary 
versus 
ty studies 
revealed that 
during the 
first two 
months’ 
antibodies 
level were 
lower after 
revaccination, 
but no 
obvious 
differences in 
differences in 
the 
composition 
of study and 
follow up, (b) 
high risk of 
bias in 
studies, and 
(c) lack of 
adjusted 
immunologica
l data. 
change in 
cases where 
past 
immunization 
is unknown. 
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review. BMC 
Infectious 
Diseases, 161
-12. 
doi:10.1186/s
12879-016-
2040-y 
 
revaccination 
dose in people 
50 years and 
older. 
antibody 
levels were 
detected.  
Revaccination 
was 
associated 
with an 
increased 
level of 
adverse 
effects; 
however, they 
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were mild and 
self-limiting. 
Vila-
Corcoles, A., 
& Ochoa-
Gondar, O. 
(2013). 
Preventing 
Pneumococcal 
Disease in the 
Elderly. Drug
s & 
To review 
data about the 
burden of 
pneumococcal 
s in the elder 
as well as 
evidence of 
immunogenici
ty, efficacy, 
and cost-
No specific 
information 
on article 
selections.  
No mention of 
number of 
articles 
identified and 
analyzed. 
This is a 
review article, 
indicates a 
literature 
search in 
PubMed, 
Scopus, and 
Cochrane 
database with 
specific terms.  
The article 
describes in 
detail PPV23 
and PCV13, 
immunogenici
ty, risk, and 
benefits 
Level 5 No limitations 
mentioned. 
I will not use 
this article to 
support 
change given 
the low level 
of evidence 
provided. 
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Aging, 30(5), 
263-276. 
doi:10.1007/s
40266-013-
0060-5 
 
effectiveness. No other 
description of 
methodology. 
Park, N. J., 
Sklaroff, L. 
M., Gross-
Schulman, S., 
Hoang, K., 
Tran, H., 
To describe a 
program in 
the Los 
Angeles 
County 
Department of 
The program 
will be 
implemented 
across more 
than 120 
Patient-
Quasi-
experiment.  
The design 
will use a 
three-pronged 
approach to 
The proposed 
plan has not 
been 
implemented, 
no results to 
review. 
Level 7 Pfizer 
provided 
funding for 
the project, 
and the 
patient can 
I will not use 
this 
information 
since the 
program was 
not 
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Campa, D., & 
... Guterman, 
J. J. (2016). 
Innovative 
Strategies 
Designed to 
Improve 
Adult 
Pneumococcal 
Immunization
s in Safety 
Net Patient-
Health 
Services to 
increase 
vaccination 
rates. 
Centered 
Medical 
Homes 
(PCMH) that 
care for more 
than 450000 
patients 
increase 
vaccination: 
Immunization 
protocol with 
provider and 
staff 
education, an 
electronic 
algorithm to 
identify at-
risk 
individuals, 
only be 
contacted if 
the 
demographic 
information is 
accurate. 
implemented.  
The article 
contains an 
adult 
immunization 
form 
indicating the 
protocol 
selected 
which can be 
used in a 
clinical 
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Centered 
Medical 
Homes. Popul
ation Health 
Management, 
19(4), 240-
247. 
doi:10.1089/p
op.2015.0099 
 
and 
automated 
multimodal 
outreach and 
scheduling. 
setting. 
Nowalk, M. 
P., Nolan, B. 
To evaluate 
the use of the 
Four primary 
care practices 
The pilot test 
required three 
PPSV rates 
increased 
Level 4 Limitations 
include (a) 
The 
information 
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D., Nutini, J., 
Ahmed, F., 
Albert, S. M., 
Susick, M., & 
Zimmerman, 
R. K. (2014). 
Success of the 
4 Pillars 
Toolkit for 
Influenza and 
Pneumococcal 
Vaccination 
four Pillars 
Toolkit, a 
standing order 
program 
(SOP), 
allowing non-
providers to 
assess the 
patient’s 
immunization 
status and 
administer 
in 
Pennsylvania, 
convenient 
sampling. 
data 
collection and 
strategies 
(a)qualitative 
data using 
onsite 
observation 
and 
interviews, 
(b)survey of 
practice staff, 
and (c) 
overall for 
high-risk 
adults but not 
for older 
adults.  
Influenza 
vaccination 
increased 
significantly 
in three of 
four sites. 
Convenient 
sampling, (b) 
unknown how 
well the 
toolkit would 
be adopted in 
offices 
without 
electronic 
medical 
records. 
will be 
considered 
but not used 
in the project. 
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in 
Adults. Journ
al For 
Healthcare 
Quality: 
Promoting 
Excellence In 
Healthcare, 3
6(6), 5-15. 
doi:10.1111/j
hq.12020 
 
vaccines.  vaccination 
rates. 
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Van 
Werkhoven, 
C. H. & 
Bonten, M. J.  
(2015).  The 
Community-
Acquired 
Pneumonia 
Immunization 
Trial in 
Adults 
(CAPiTA): 
The article 
summarizes 
the main 
results of the 
CAPiTA 
study where 
efficacy and 
safety of 
PCV13 was 
assessed in 
immunocomp
etent 
A total of 
84,946 
participants 
were included 
and enrolled 
between 15 
September 
2008 and 30 
January 2010. 
Subjects were 
randomized in 
a 1:1 ratio to 
receive 
PCV13 or 
placebo and 
followed up 
for a mean 
time of 4 
years. 
PCV13 is safe 
and 
effectively 
reduces the 
incidence of 
CAP and IPD 
in elderly over 
65 years of 
age.  
Level 2 No limitations 
included in 
this article. 
I will use this 
information to 
support 
change due to 
the 
methodology 
and results. 
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What is the 
future of 
pneumococcal 
conjugate 
vaccination in 
elderly?  
Future 
Microbiology, 
10(9), 1405+.  
Retrieved 
from 
http://go.galeg
community-
dwelling 
individuals of 
age 65 and 
above living 
in The 
Netherlands  
he most 
important 
eligibility 
criteria were 
the age of 65 
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roup.com.ezpr
oxy.liberty.ed
u/ps/i.do?p=A
ONE&u=vic_
liberty&id=G
ALE%7CA43
0076861&v=
2.1&it=r&sid
=summon# 
 
years or 
above, not 
living in a 
nursing home 
or long-term 
care facility 
and being 
immunocomp
etent  
Hoshi, S., 
Kondo, M., & 
To address the 
efficiency of 
All 
individuals 
A cost-
effectiveness 
Compared to 
the current 
Level 4 Limitations 
include (a) 
I will not 
consider this 
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Okubo, I. 
(2015). 
Economic 
Evaluation of 
Immunization 
Program of 
23-Valent 
Pneumococcal 
Polysaccharid
e Vaccine and 
the Inclusion 
of 13-Valent 
alternative 
strategies of 
PPSV23 
programs and 
efficiency of 
PCV13 
inclusion in 
the list of the 
single-dose 
vaccine in the 
national 
immunization 
eligible for 
the subsidized 
PPSV 23. 
analysis with 
Markiv 
modeling 
from payers’ 
perspective. 
The strategies 
selected were 
(a) current 
PPSV23 
strategy, (b) 
65 to 85 years 
of age and (c) 
PPSV 23, the 
65 to 85 
strategy cost 
less but 
gained less 
while the 
incremental 
cost-
effectiveness 
of the 65 
years and 
older was 
insufficient 
data of 
municipalities
, (b) did not 
consider the 
herd effect of 
PCV7 and 
PCV 13, and 
(c) did not 
account for 
the 
advertising 
study since it 
deals mainly 
with the 
economic 
aspect of a 
specific 
vaccine. 
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Pneumococcal 
Conjugate 
Vaccine in the 
List for 
Single-Dose 
Subsidy to the 
Elderly in 
Japan. Plos 
ONE, 10(10), 
1-16. 
doi:10.1371/j
ournal.pone.0
program. 65 years and 
older. 
better. costs of 
manufacturers
. 
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139140 
 
Huss, A., 
Scott, P., 
Stuck, A. E., 
Trotter, C., & 
Egger, M. 
(2009). 
Efficacy of 
pneumococcal 
vaccination in 
adults: a 
To evaluate 
the vaccine’s 
efficacy on 
clinical 
outcomes as 
well as the 
methodologic 
quality of the 
trials. 
516 articles 
were 
identified, and 
22 were 
analyzed. 
Systematic 
review and 
meta-analysis 
are evaluating 
clinical trials 
that compared 
pneumococcal 
polysaccharid
e vaccine with 
a control. 
The results for 
all-cause 
mortality in 
double-blind 
trials were 
similar to 
those in all 
trials 
combined. 
There was 
Level 1 Limitations 
include (a) 
erroneous 
diagnosis, 
(b)adverse 
events were 
not 
systematically 
examined as 
planned. 
I will consider 
this 
information 
when 
planning and 
designing the 
intervention 
and 
measuring 
outcomes. 
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meta-
analysis. CMA
J: Canadian 
Medical 
Association 
Journal, 180(
1), 48-58. 
 
Researchers 
examined 
rates of 
pneumonia 
and death, 
taking the 
methodologic 
quality of the 
trials into 
consideration. 
little evidence 
of vaccine 
protection 
among elderly 
patients or 
adults with 
chronic illness 
in analyses of 
all trials. 
Schneeberg, 
A., Bettinger, 
To improve 
the 
863 
participants 
Cross-
sectional 
58% of 
participants 
Level 4 Participants 
received the 
I will use this 
information 
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J. A., McNeil, 
S., Ward, B. 
J., Dionne, 
M., Cooper, 
C., & ... 
Halperin, S. 
A. (2014). 
Knowledge, 
attitudes, 
beliefs, and 
behaviors of 
older adults 
understanding 
of factors 
influencing 
vaccination. 
completed the 
survey, 
inclusion and 
exclusion 
criteria were 
included. 
study where a 
self-
administered 
survey was 
completed by 
seniors 
participating 
in a clinical 
trial of 
seasonal 
influenza 
vaccine at 
indicated 
receiving the 
pneumococcal 
vaccine.  The 
stronger 
factors were 
being offered 
the vaccine by 
the primary 
care provider.  
Other 
variables 
influenza 
vaccine, 
meaning they 
are agreeable 
with 
immunization. 
when 
considering 
educational 
material. 
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about 
pneumococcal 
immunization, 
a Public 
Health 
Agency of 
Canada / 
Canadian 
Institutes of 
Health 
Research 
Influenza 
eight centers 
in Canada. 
influencing 
the decision 
of receiving 
the vaccine 
include 
having heard 
about it and 
agreeing with 
its 
importance. 
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Research 
Network 
(PCIRN) 
investigation. 
BMC Public 
Health, 14(1), 
1-16. 
doi:10.1186/1
471-2458-14-
442 
 
Mandell, L. The article is The The process The Level 1 No specific I will use this 
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A., 
Wunderink, 
R. G., 
Anzueto, A., 
Bartlett, J. G., 
Campbell, G. 
D., Dean, N. 
C., & ... 
Whitney, C. 
G. (2007). 
Infectious 
Diseases 
a guideline by 
the Infectious 
Diseases 
Society of 
America 
(IDSA) and 
the American 
Thoracic 
Society (ATS) 
to be used by 
primarily for 
use by 
guidelines 
recommendati
on are graded 
and the 
strength 
evaluated. 
of guideline 
development 
started with 
the selection 
of committee 
co-chairs by 
the presidents 
of the IDSA 
and ATS, as 
well as other 
leaders in the 
respective 
guidelines 
address (a) 
site of care 
decisions, (b) 
diagnostic 
testing, (c) 
antibiotic 
treatment, (d) 
other 
treatment 
recommendati
ons, (e) 
limitations 
noted. 
evidence to 
support 
change since 
it is a 
recommendati
on by two 
organizations 
and the data 
provided is 
based on 
evidence-
based 
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Society of 
America/Ame
rican Thoracic 
Society 
consensus 
guidelines on 
the 
management 
of 
community-
acquired 
pneumonia in 
emergency 
medicine 
physicians, 
hospitalists, 
and primary 
care 
practitioners. 
societies.   unresponsive 
to treatment, 
and (f) 
prevention. 
practice. 
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adults. Clinica
l Infectious 
Diseases: An 
Official 
Publication 
Of The 
Infectious 
Diseases 
Society Of 
America, 44 
Suppl 2S27-
S72. 
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Brown, J. D., 
Harnett, J., 
Chambers, R., 
& Sato, R. 
(2018). The 
relative 
burden of 
community-
acquired 
pneumonia 
hospitalizatio
To compare 
the financial 
burden of 
CAP with 
other 
illnesses. 
A total of 
1,949,352 
individuals 
were included 
in the study; 
inclusion 
criteria are as 
followed:  
Adults aged 
65 to 89 years 
with 
This 
retrospective 
cohort 
analysis of 
claims 
between 2014 
and 2015 and 
compared 
Hospitalizatio
n for CAP to 
myocardial 
Overall, CAP 
had a higher 
burden of 
hospitalizatio
n with 
disproportiona
te prevention 
efforts. 
Level 4 Limitations 
include (a) 
lack of certain 
information in 
the database 
and errors or 
omissions in 
claims coding, 
(b) data from 
a single 
insurer, (c) 
I will use this 
information to 
support the 
project since 
it provides 
information 
on the lack of 
prevention. 
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ns in older 
adults: a 
retrospective 
observational 
study in the 
United 
States. BMC 
Geriatrics, 18
(1), 92. 
doi:10.1186/s
12877-018-
0787-2 
continuous 
Medicare 
Advantage 
with 
Prescription 
Drug Plan 
(MAPD) 
enrollment in 
the dates of 
the study.  
infarction, 
stroke, and 
osteoporotic 
fractures.  
 
limited the 
cohort to 
members who 
did not have 
one or more 
hospitalizatio
ns in 2014, 
and (d) 
primary 
hospital 
diagnosis. 
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Drijkoningen, 
J.C. & Rohde, 
G U.  (2014).  
Pneumococcal 
infection in 
adults: 
Burden of 
disease.  
Clinical 
Microbiology 
and Infection, 
The article 
provides 
detail 
information 
on the 
different 
aspects of the 
pneumococcal 
disease. 
No sample. No specific 
methods 
described, the 
article 
provides 
clinical 
information. 
No results. Level 7 No limitations 
described. 
The 
information in 
this article 
provides an 
understanding 
of the 
pneumococcal 
disease. 
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20, 545-51.  
Doi: 
10.1111/1269
-0691.12461 
 
Tuti, T., 
Nzinga, J., 
Njoroge, M., 
Brown, B., 
Peek, N., 
English, M., 
& ... van der 
The assess the 
effectiveness 
of electronic 
audit and 
feedback (e-
A&F) 
interventions 
Researchers 
analyzed 
seven studies 
comprising of 
81,700 
patients being 
cared for by 
Systematic 
analysis.  
Data were 
extracted by 
two 
independent 
review 
Given the 
high 
heterogeneity 
of identified 
studies, the 
effects of e-
A&F were 
Level 1 Limitations 
include (a) 
use of 
electronic 
intervention 
as a keyword, 
and (b) 
I will use this 
evidence in 
the project, 
indicating that 
electronic 
audit and 
feedback is 
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Veer, S. N. 
(2017). A 
systematic 
review of 
electronic 
audit and 
feedback: 
intervention 
effectiveness 
and use of 
behaviour 
change 
in primary 
care and acute 
care and to 
identify 
theoretical 
mechanisms 
of behavior 
change.   
329 
healthcare 
professionals/ 
primary care 
facilities.  E-
A&F 
interventions 
were 
described as a 
summary of 
clinical 
performance 
authors, who 
determined 
the domains 
within the 
Theoretical 
Domains 
Framework 
(TDF).  
Authors 
completed a 
meta-analysis 
of e-A&F 
found to be 
highly 
variable. 
included five 
studies in the 
meta-analysis 
regardless of 
their risk of 
bias. 
variable, and 
will not be 
recommended 
for this 
project. 
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theory. Imple
mentation 
Science, 121-
20. 
doi:10.1186/s
13012-017-
0590-z 
 
delivered 
through an 
interactive 
computer 
interface to 
healthcare 
providers. 
effectiveness 
and a 
narrative 
analysis of the 
nature and 
patterns of 
TDF domains 
and potential 
links with the 
intervention 
effect. 
Ivers, N., To assess the 140 studies Systematic Audit and Level 1  I will use this 
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Jamtvedt, G., 
Flottorp, S., 
Young, J. M., 
Odgaard-
Jensen, J., 
French, S. D., 
& ... Oxman, 
A. D. (2012). 
Audit and 
feedback: 
effects on 
professional 
use of audit 
and feedback 
on clinical 
practice and 
patient 
outcomes, as 
well as to 
examine the 
factors that 
might explain 
its variation in 
effectiveness. 
were included 
in the review, 
with 82 
comparisons 
from 49 
studies with 
dichotomous 
outcomes 
included in 
the primary 
analysis.  
Inclusion and 
review of 
randomized 
controlled 
trials of audit 
and feedback.  
Risk of bias 
and the effects 
of 
interventions 
were 
discussed in 
detail. 
feedback lead 
to small but 
potentially 
important 
improvements 
in 
professional 
practice.  Its 
effectiveness 
depends on 
how the 
feedback is 
article to 
support the 
use of audit 
and feedback 
as an 
intervention 
in the project.  
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Appendix E 
Human Resources Letter of Approval 
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Appendix F 
Permission to Use the Iowa Model 
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Appendix G 
CPD Reaction Questionnaire 
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Appendix H 
CPD Reaction Questionnaire Scores on Items and Constructs 
 
Note.  Retrieved from Légaré, F., Freitas, A., Trucotte, S., Bourdas, F., Jacuques, A., Luconi, F., 
…Labrecque, M.  (2017).  Responsiveness of a simple tool for assessing change in behavioral 
intention after continuing professional development activities.  PLos, One, 12(5), e0176678.  doi: 
10.1371/journal.pone.0176678 
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Appendix I 
CPD Questionnaire Permission to Use 
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Appendix J 
Pneumonia Vaccine Documentation Spreadsheet Template 
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Appendix K 
Master List: Provider Identification 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Provider Name Assigned Provider 
ID Code 
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         Appendix L 
Participant Consent Template 
CONSENT FORM 
Increase in Pneumococcal vaccination in adults over 65 years of age in a Federally 
Qualified Health Center 
Mara Dominguez  
Liberty University 
School of Nursing 
 
You are invited to be in a research study on Pneumococcal vaccination rate in adults over the age 
of 65 years.  You were selected as a possible participant because you are a provider at Capital 
Area Health Network (CAHN) employed during the periods between 12/04/2017 to 01/03/2018  
and 12/04/2018 to 01/03/2019.  Please read this form and ask any questions you may have before 
agreeing to be in the study. 
 
Mara Dominguez, a doctoral candidate in the School of Nursing at Liberty University, is 
conducting this study.  
 
Background Information: The purpose of this study is to implement a chart audit, feedback, 
and provider educational intervention aiming at increasing the rate of Pneumococcal vaccination 
rates in adults older than 65 years of age at a Federally Qualified Health Center.   
 
Procedures: If you agree to be in this study, I would ask you to do the following things: 
1. Participate in an educational intervention lasting less than 10 minutes. 
2. Participate in a chart audit feedback process lasting less than five minutes.  
3. Complete a questionnaire to determine your intent to change and improve your practice 
based on the information provided, taking about five minutes.   
4.  
Risks: The risks involved in this study are minimal, which means they are equal to the risks you 
would encounter in everyday life. 
 
Benefits: The direct benefits participants should expect to receive from taking part in this study 
are to increase their knowledge about current guidelines and an insight into their current practice.  
The project will provide feedback on their performance related to pneumococcal vaccination.   
 
Benefits to society include an increase in the pneumococcal vaccination rate in adults over the 
age of 65 years, decreasing morbidity and mortality in this population 
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Compensation: Participants will not be compensated for participating in this study.  
 
Confidentiality: The records of this study will be kept private. In any sort of report, I might 
publish, I will not include any information that will make it possible to identify a subject.  
Research records will be stored securely, and only the researcher will have access to the records.  
 
Participant’s privacy will be maintained using a master list and providers’ identification form. A 
questionnaire with provider's name will be kept locked.  The provider feedback report will be de-
identified, and the educational feedback will not include the individual provider performance 
reports. 
Data will be stored in a password protected computer and only accessible by the project leader.  
The questionnaire results will be stored in a safe and secure location, locked, only accessible by 
the project leader.  All the data collected will be stored for three years, after this time, electronic 
data will be deleted using software designed to remove all data from the storage device.  Hard 
copies will be shredded and recycled.  The disposal of the data will be documented indicating 
how and when it was completed.   
Voluntary Nature of the Study: Participation in this study is voluntary. Your decision whether 
or not to participate will not affect your current or future relations with Liberty University and 
CAHN.  If you decide to participate, you are free to not answer any question or withdraw at any 
time without affecting those relationships.  
 
How to Withdraw from the Study: If you choose to withdraw from the study, please contact 
the researcher at the email address/phone number included in the next paragraph. Should you 
choose to withdraw, data collected from you, will be destroyed immediately and will not be 
included in this study.  
 
Contacts and Questions: The researcher conducting this study is Mara Dominguez. You may 
ask any questions you have now. If you have questions later, you are encouraged to contact her 
at 703-217-1617 or mjdominguez@liberty.edu. You may also contact the researcher’s faculty 
chair, Dr. Dorothy Murphy at dlmurphy1@liberty.edu.  
 
If you have any questions or concerns regarding this study and would like to talk to someone 
other than the researcher, you are encouraged to contact the Institutional Review Board, 1971 
University Blvd., Green Hall Ste. 2845, Lynchburg, VA 24515 or email at irb@liberty.edu.   
 
Please notify the researcher if you would like a copy of this information for your records. 
 
Statement of Consent: I have read and understood the above information. I have asked 
questions and have received answers. I consent to participate in the study. 
 
______________________________________________________________________________ 
Signature of Participant        Date 
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______________________________________________________________________________ 
Signature of Investigator        Date 
 
 
